Eli Lilly (LLY)

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash deal valued at approximately $6.7 billion. The move, priced at $53.00 per share, marks the culmination of one of the most dramatic corporate turnarounds [...]

Even if you're starting with $0 today, you can still build up a million-dollar portfolio with regular monthly investments.

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

First Bancorp delivers banking, lending, and digital financial services across the Carolinas, serving individuals and local businesses.

As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total deal values surged to a record-breaking $813.3 billion in Q1, a staggering leap that signals a

The company recently obtained approval for a higher-dose version of Wegovy.

Eli Lilly will discontinue select insulin products in EU markets by Q2 2027, citing commercial reasons as regulators monitor supply impact.

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026. Regulatory filings and recent market data indicate a coordinated accumulation by major asset managers, who are increasingly viewing the California-based biotech giant

As of March 23, 2026, the American corporate engine has proven itself to be remarkably high-revving, even as the global landscape shifts beneath it. Despite a volatile start to the year characterized by a spike in energy prices and the implementation of sweeping new fiscal policies, the S&P 500

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court revives Actos litigation risks.

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook, titled "Think Big, Build Bigger," predicting a massive 15% increase in merger and acquisition deal

Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February.

Buying $1,000 of each of these stocks should pay off nicely over the long run.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Explore how each ETF’s unique sector focus and fee structure could impact your dividend strategy and long-term portfolio mix.

One of these assets is catalyst-driven; the other isn't.

A catalyst for stock performance may be just ahead.

This company has a habit of beating the market over long periods.

The Wegovy pill could change Hims & Hers' growth in 2026.

The promise of a mid-March market recovery vanished this week as a short-lived "relief rally" gave way to a wave of "buyer’s remorse," leaving investors scrambling for cover. What began on Monday as a hopeful bounce driven by artificial intelligence optimism and a temporary dip in energy costs ended

These companies have impressive track records of navigating the biggest challenges in their industry.

Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.

Both have plenty to offer investors, but one has a better outlook.